TScan Therapeutics, Inc.
No enriched coverage for $TCRX in the last 7 days.
No SEC Form 4 filings for $TCRX in the last 30 days.
See all $TCRX insider activity →TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +20.00% and -21.61%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +60.80% and +50.63%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for ...
TScan Therapeutics reported a significant earnings surprise (+20%) but a larger revenue miss (-21.61%) for Q3 2025. This mixed result indicates potential volatility, with the stock likely to experience short-term fluctuations. The positive earnings surprise may provide a short-term boost, but the revenue miss could weigh on investor sentiment.
TCRX shows a neutral sentiment with no significant recent developments affecting its outlook. The relevance score of 0.20698 suggests limited influence from the ARCT news.
The news pertains specifically to TScan Therapeutics' development and regulatory progress, with limited direct impact on TCRX, which is a different entity in the biotech sector.
The company's positive FDA engagement and strategic focus on TSC-101 suggest potential near-term catalysts, possibly leading to stock appreciation. However, the pause in enrollment and strategic shifts introduce some execution risk.
Minimal to no impact expected on TCRX.
alphai scores every news story that mentions TCRX with an AI model for sentiment and relevance, and aggregates insider trades from TScan Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +20.00% and -21.61%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min readArcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +60.80% and +50.63%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min readPositive end of Phase I meeting and agreement reached with FDA on pivotal study design for ...
2 min readPositive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to prioritize heme development; reiterates planned data readout in Q1 2026
2 min readWILMINGTON, Del., Oct. 17, 2025 ( GLOBE NEWSWIRE ) -- Prelude Therapeutics Incorporated ( NASDAQ:PRLD ) , a clinical-stage precision oncology company, today announced the appointment of Katina Dorton to its Board of Directors, effective today.
2 min readWILMINGTON, Del., Oct. 17, 2025 ( GLOBE NEWSWIRE ) -- Prelude Therapeutics Incorporated ( Nasdaq: PRLD ) , a clinical-stage precision oncology company, today announced the appointment of Katina Dorton to its Board of Directors, effective today.
2 min readWALTHAM, Mass., Sept. 17, 2025 ( GLOBE NEWSWIRE ) -- TScan Therapeutics, Inc.
3 min readTScan Therapeutics (TCRX) delivered earnings and revenue surprises of 0.00% and +58.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min readKING OF PRUSSIA, Pa., June 09, 2025 ( GLOBE NEWSWIRE ) -- SEED Therapeutics Inc. ( "SEED" ) , a biotechnology company pioneering targeted protein degradation ( TPD ) through the discovery of innovative molecular glues and bifunctional degraders, today announced the appointment of Dr. Bill ...
2 min readWALTHAM, Mass., May 28, 2025 ( GLOBE NEWSWIRE ) -- TScan Therapeutics, Inc.
3 min read
